An emerging option for patients with CKD secondary to several kidney pathologies is dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and an established therapy for patients with type 2 diabetes (T2D) that has demonstrated significant reductions in cardiovascular- and kidney-related outcomes [6–9]. This evidence concerns the gene SLC5A2 and chronic kidney disease.